Chemed Corporation

NYSE:CHE Rapport sur les actions

Capitalisation boursière : US$5.8b

Chemed Croissance future

Future contrôle des critères 1/6

Chemed devrait augmenter ses bénéfices et ses revenus de 12.9% et de 6.3% par an respectivement, tandis que le BPA devrait croître de croître de 15.5% par an.

Informations clés

12.9%

Taux de croissance des bénéfices

15.53%

Taux de croissance du BPA

Healthcare croissance des bénéfices18.9%
Taux de croissance des recettes6.3%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour04 Jun 2026

Mises à jour récentes de la croissance future

Article d’analyse • Oct 31

Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...

Recent updates

Mise à jour du récit • Jun 01

CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns

Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.
Mise à jour du récit • Apr 27

CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns

Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).
Mise à jour du récit • Apr 10

CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns

Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.
Mise à jour du récit • Mar 27

CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns

Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).
Mise à jour du récit • Mar 10

CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns

Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).
Nouveau récit • Feb 27

Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance

Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?
Mise à jour du récit • Feb 24

CHE: Stable Margins And Expanded Buybacks Will Support Future Upside

Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).
Mise à jour du récit • Feb 10

CHE: Stable Margins And Consistent Assumptions Will Support Future Upside

Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.
Mise à jour du récit • Jan 23

CHE: Share Buybacks And Margin Outlook Will Support Future Upside

Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.
Article d’analyse • Jan 16

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Article d’analyse • Oct 31

Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...
Article d’analyse • Oct 24

Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...
Seeking Alpha • Oct 06

Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy

Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking Alpha
Mise à jour du récit • Sep 03

New Florida CON Sites Will Advance Home-Based And Hospice Care

Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.
Article d’analyse • Jul 07

Chemed Corporation (NYSE:CHE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$614 Chemed's US$473 share...
Article d’analyse • Jun 18

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

With a price-to-earnings (or "P/E") ratio of 25.9x Chemed Corporation ( NYSE:CHE ) may be sending bearish signals at...
User avatar
Nouveau récit • Aug 25

Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward

Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.
Seeking Alpha • Aug 16

Chemed Remains A Buy On Long-Term Economics

Summary Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital that's been employed into its operations. Management has an extensive reinvestment runway to redeploy surplus funds and grow the intrinsic worth of the business. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NYSE:CHE - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20283,015N/AN/AN/A1
12/31/20272,8583273464224
12/31/20262,6912953213914
3/31/20262,541260377444N/A
12/31/20252,530265325388N/A
9/30/20252,531279360420N/A
6/30/20252,512290371427N/A
3/31/20252,489309315366N/A
12/31/20242,431302368417N/A
9/30/20242,377302313361N/A
6/30/20242,336301253300N/A
3/31/20242,293283302354N/A
12/31/20232,264273273330N/A
9/30/20232,225245259322N/A
6/30/20232,187226280345N/A
3/31/20232,165240208269N/A
12/31/20222,135250253310N/A
9/30/20222,129262220273N/A
6/30/20222,141277284334N/A
3/31/20222,142267249303N/A
12/31/20212,139269250309N/A
9/30/20212,132308271332N/A
6/30/20212,121303283344N/A
3/31/20212,091329450507N/A
12/31/20202,080319430489N/A
9/30/20202,069271410466N/A
6/30/20202,021263413470N/A
3/31/20201,992231258317N/A
12/31/20191,939220N/A301N/A
9/30/20191,874209N/A294N/A
6/30/20191,837201N/A275N/A
3/31/20191,806205N/A296N/A
12/31/20181,783206N/A287N/A
9/30/20181,753206N/A202N/A
6/30/20181,727190N/A183N/A
3/31/20181,700113N/A159N/A
12/31/20171,66798N/A162N/A
9/30/20171,64276N/A198N/A
6/30/20171,61767N/A162N/A
3/31/20171,592114N/A197N/A
12/31/20161,577109N/A135N/A
9/30/20161,572106N/A187N/A
6/30/20161,566108N/A175N/A
3/31/20161,557111N/A166N/A
12/31/20151,543110N/A172N/A
9/30/20151,524110N/A172N/A
6/30/20151,496106N/A135N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CHE ( 12.9% par an) est supérieure au taux d'épargne ( 3.5% ).

Bénéfices vs marché: Les bénéfices de CHE ( 12.9% par an) devraient croître plus lentement que le marché US ( 16.9% par an).

Croissance élevée des bénéfices: Les bénéfices de CHE devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CHE ( 6.3% par an) devrait croître plus lentement que le marché de US ( 11.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CHE ( 6.3% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CHE devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/08 03:59
Cours de l'action en fin de journée2026/06/08 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Chemed Corporation est couverte par 10 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Adam FeinsteinBarclays
Joanna Sylvia GajukBofA Global Research
Peter MartinCitizens JMP Securities, LLC